Bayer AG has secured U.S. Food and Drug Administration approval for Sunharbo, or asundexian, making the 50 mg once-daily tablet the first Factor XIa inhibitor approved in the United States. The medicine is approved in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
The November 9 decision is based on the 12,327-patient Phase 3 OCEANIC-STROKE trial, in which asundexian reduced the risk of recurrent ischemic stroke by 26% compared with placebo when both groups received background antiplatelet therapy. Ischemic stroke occurred in 6.2% of patients assigned to asundexian and 8.4% receiving placebo over a median treatment period of 14.2 months, producing a hazard ratio of 0.74.
The approval is particularly significant because asundexian’s development history includes one of the most prominent setbacks in the Factor XIa field. Bayer stopped the separate OCEANIC-AF Phase 3 trial in 2023 after asundexian proved less effective than apixaban at preventing stroke or systemic embolism in patients with atrial fibrillation. Sunharbo is therefore not approved for stroke prevention in atrial fibrillation, and its successful development in non-cardioembolic stroke demonstrates that the clinical value of Factor XIa inhibition may depend heavily on the disease setting and comparator.
The commercial timing also matters for Bayer. Its older anticoagulant Xarelto is facing patent-related erosion, with third-quarter 2026 sales declining sharply, while management has been looking to new cardiovascular medicines to rebuild pharmaceutical growth. Sunharbo now becomes one of the most important tests of whether Bayer can translate a first-in-class mechanism into a meaningful commercial franchise.
Why is the 26% reduction in recurrent ischemic stroke clinically important?
Patients who survive an ischemic stroke remain at considerable risk of another event, particularly during the period immediately after the initial stroke. OCEANIC-STROKE tested whether adding Factor XIa inhibition to standard antiplatelet therapy could reduce that residual risk without creating the substantial bleeding burden associated with stronger anticoagulation.
The trial enrolled adults within 72 hours of a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Patients were randomly assigned in double-blind fashion to receive asundexian 50 mg once daily or placebo, with antiplatelet treatment used in both groups according to the study protocol and clinical practice.
The primary efficacy result was statistically significant. Recurrent ischemic stroke occurred in 384 of 6,162 patients receiving asundexian compared with 518 of 6,165 patients receiving placebo, corresponding to rates of 6.2% and 8.4%. The hazard ratio of 0.74 had a 95% confidence interval of 0.65 to 0.84, with a p-value below 0.001.
The absolute difference was approximately 2.2 percentage points over the observed period. That figure is smaller than the 26% relative risk reduction but remains relevant in secondary stroke prevention because the eligible population is large and recurrent events can produce additional disability or death.
Other cardiovascular outcomes moved in the same direction. The composite of cardiovascular death, myocardial infarction or stroke occurred in 9.2% of asundexian patients compared with 11.1% on placebo. These secondary findings strengthen the overall efficacy profile, although the approval is centred on reducing stroke risk rather than establishing a broad cardiovascular mortality benefit.
Why does the bleeding result make Factor XIa inhibition different from traditional anticoagulation?
The central scientific attraction of Factor XIa inhibition has always been the possibility of separating protection from thrombosis from the physiological processes needed to stop everyday bleeding. Factor XI contributes to pathological clot propagation but appears to play a less essential role in normal haemostasis than targets such as Factor Xa or thrombin.
OCEANIC-STROKE provides important clinical support for that concept, but the result requires careful wording. International Society on Thrombosis and Haemostasis major bleeding occurred in 1.9% of asundexian patients and 1.7% of placebo patients, producing a hazard ratio of 1.10 with a confidence interval that crossed 1.0. The difference was not statistically significant.
That does not mean Sunharbo has no bleeding risk. The FDA specifically noted that major bleeding was increased with Sunharbo among patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding was also more frequent with asundexian.
A detailed bleeding analysis found any gastrointestinal bleeding in 3.0% of asundexian patients compared with 2.4% on placebo. Lower gastrointestinal bleeding occurred in 1.7% versus 1.0%, respectively, while symptomatic intracranial haemorrhage was uncommon in both groups at 0.7% and 0.6%.
The value proposition is therefore not that Factor XIa inhibition eliminates anticoagulant bleeding. The more defensible interpretation is that asundexian reduced ischemic stroke without a statistically significant increase in overall major bleeding in this particular trial population, while certain bleeding categories and patient subgroups still require attention.
How did asundexian recover after the OCEANIC-AF Phase 3 failure?
The approval completes an unusually dramatic reversal for the programme. In November 2023, an independent monitoring committee recommended stopping OCEANIC-AF early because asundexian showed inferior efficacy to apixaban in patients with atrial fibrillation at elevated risk of stroke.
The final study results made the scale of the problem clear. Stroke or systemic embolism occurred in 1.3% of patients assigned to asundexian compared with 0.4% receiving apixaban, producing a hazard ratio of 3.79. Major bleeding was lower with asundexian, but that safety advantage could not compensate for inadequate protection against thromboembolism.
Bayer nevertheless continued OCEANIC-STROKE because the independent monitoring committee did not identify the same efficacy problem in that programme. The decision proved critical because the clinical setting is fundamentally different.
Atrial fibrillation produces thrombi through mechanisms that require a level of anticoagulation against which apixaban is already highly effective. Non-cardioembolic stroke, by contrast, is usually managed with antiplatelet therapy rather than chronic full-dose oral anticoagulation, creating a different therapeutic opportunity for adding Factor XIa inhibition.
The two studies therefore should not be viewed as contradictory evidence about one universal use of the drug. They show that asundexian can fail against an established anticoagulant in one disease setting while still provide incremental benefit on top of antiplatelet therapy in another.
That distinction is reflected directly in the FDA label. Sunharbo is not approved for stroke prevention in atrial fibrillation.
Who exactly is eligible for Sunharbo under the FDA label?
The approved population includes adults following a recent mild-to-moderate non-cardioembolic ischemic stroke, defined in the regulatory material as a National Institutes of Health Stroke Scale score of 15 or less, or adults who have experienced a high-risk transient ischemic attack. Treatment is used in combination with antiplatelet therapy.
That population definition matters because stroke is not one disease mechanism. Cardioembolic strokes caused by atrial fibrillation or other cardiac sources are treated differently from non-cardioembolic strokes related to atherosclerosis, small-vessel disease or other mechanisms.
The FDA approval therefore should not be broadened into a general claim that Sunharbo prevents all recurrent strokes. Appropriate determination of stroke mechanism remains an important part of treatment selection.
Sunharbo is given as a 50 mg tablet once daily. The FDA does not recommend use in patients with moderate or severe hepatic impairment, and concomitant treatment with medicines that are both P-glycoprotein and strong CYP3A4 inducers is not recommended because they can reduce asundexian exposure and potentially diminish effectiveness.
The label also contains procedural instructions. Sunharbo should generally be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolytic treatment for acute ischemic stroke.
Why could the first Factor XIa approval reshape the anticoagulant development race?
Factor XIa has attracted substantial pharmaceutical investment because current anticoagulants often force clinicians to balance prevention of stroke or thrombosis against bleeding. A drug capable of reducing pathological clot formation with a smaller haemostatic penalty could create opportunities in patients who are difficult to treat with traditional anticoagulation.
Bayer is now the first company to convert that scientific hypothesis into a U.S. marketing approval. The achievement gives Sunharbo an early regulatory lead over several competing Factor XI or Factor XIa programmes, including agents being developed by major pharmaceutical companies.
That lead does not guarantee commercial dominance. Different Factor XI programmes are being studied in different clinical settings, including atrial fibrillation, venous thromboembolism and other cardiovascular indications, and some competitors use antibodies rather than oral small molecules.
The OCEANIC-AF failure also acts as a warning against treating the mechanism as universally superior to established anticoagulants. Factor XIa inhibition may ultimately become a class with highly indication-specific strengths rather than a wholesale replacement for Factor Xa inhibitors.
Sunharbo nevertheless establishes an important regulatory precedent. For the first time, physicians in the United States will have an approved medicine targeting Factor XIa, allowing real-world experience to begin testing whether the theoretical balance between thrombosis prevention and bleeding translates outside clinical trials.
What does the approval mean for Bayer as Xarelto faces patent erosion?
Bayer’s cardiovascular portfolio is in transition. Xarelto was once one of its most important pharmaceutical growth products, but third-quarter sales fell 30.7% on a currency and portfolio-adjusted basis as patent expirations and generic competition continued to pressure the franchise.
Sunharbo provides Bayer with a new cardiovascular product at a moment when the company needs replacement growth. Management has described asundexian as an important pipeline opportunity, and successful uptake could help offset some of the structural decline in older products.
The company is entering launch preparation from a stronger pharmaceutical performance base than it had several years ago. Bayer reported group third-quarter sales of €10.05 billion, while Pharmaceuticals drove much of the improvement and management raised parts of its full-year outlook.
Investor sentiment has also improved substantially. Bayer shares closed November 10 at €57.08 on Xetra, up about 0.8% for the session after gaining 1.9% on November 9. The shares were roughly 30% higher over one month and more than 50% higher over six months, although the rally reflects multiple corporate developments and should not be attributed solely to Sunharbo.
The commercial challenge will be persuading neurologists and other stroke specialists that adding another antithrombotic medicine provides enough incremental protection to justify cost, monitoring and bleeding considerations. Reimbursement and formulary access will also influence how quickly the product penetrates routine care.
Why does the China approval strengthen Bayer’s launch position?
China approved asundexian in late October under the same Sunharbo brand for secondary stroke prevention, making it the first Factor XIa inhibitor to receive marketing authorisation anywhere in the world. The U.S. decision now gives Bayer approval in two of the world’s largest pharmaceutical markets within a matter of weeks.
The Chinese approval is commercially relevant because stroke burden is particularly high in China. It also provides Bayer with an opportunity to build experience with the new mechanism across very different healthcare systems.
Regulatory applications remain under review in additional markets. Approval in one jurisdiction does not predict approval elsewhere, and local labels, reimbursement policies and treatment guidelines may differ substantially.
The rapid sequence of China and U.S. decisions nevertheless shifts asundexian from a pipeline asset into a global commercialisation programme. That transition places greater emphasis on manufacturing, market access, physician education and pharmacovigilance rather than clinical development alone.
What safety signals will matter most once Sunharbo enters routine use?
The OCEANIC-STROKE dataset is large, but post-market use will expose a much broader and older population with more comorbidities, medications and procedural needs. The FDA’s observation that major bleeding was increased among patients older than 75 years will therefore receive particular attention.
Gastrointestinal bleeding is another likely focus. Although overall major bleeding was statistically similar between groups, the increase in lower gastrointestinal bleeding suggests that the mechanism does not remove clinically relevant mucosal bleeding risk.
Real-world treatment duration will also matter. Patients in OCEANIC-STROKE were treated for a median of 14.2 months, while secondary stroke prevention may extend for substantially longer periods depending on clinical practice and future evidence.
Drug interactions could influence use as well. Strong enzyme and transporter inducers can reduce asundexian concentrations, while patients recovering from stroke often take multiple medicines for hypertension, diabetes, lipid control and other cardiovascular conditions.
Post-marketing safety surveillance should therefore clarify whether the favourable major bleeding balance observed in the trial remains stable in older and medically complex patients.
Can Sunharbo become a major cardiovascular franchise after such a mixed development history?
The FDA approval validates one of the central scientific ideas behind Factor XIa inhibition, but only within a precisely defined clinical context. In patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack already receiving antiplatelet therapy, adding asundexian reduced recurrent ischemic stroke without a statistically significant increase in overall major bleeding.
The programme’s earlier failure in atrial fibrillation prevents the story from becoming a simplistic narrative about a universally safer new anticoagulant. Against apixaban, asundexian failed to provide adequate thromboembolic protection. Against placebo on top of antiplatelet therapy after non-cardioembolic stroke, it delivered a clinically and statistically meaningful benefit.
That contrast may ultimately define the drug’s value more clearly than an uninterrupted development programme would have done. Factor XIa inhibition appears capable of providing additional antithrombotic protection without the full bleeding burden of conventional anticoagulation in selected settings, but it cannot be assumed to replace highly effective anticoagulants where stronger suppression of coagulation is required.
The next test moves from regulatory science to clinical practice. Bayer must show that neurologists adopt Sunharbo, payers cover it, older patients can be treated safely and the trial’s reduction in recurrent stroke persists across a broader real-world population.
If those pieces fall into place, Sunharbo could become a meaningful successor growth product as Xarelto declines and establish Bayer at the front of a new anticoagulation class. If bleeding concerns, reimbursement barriers or modest absolute benefit constrain uptake, the FDA’s first Factor XIa approval may prove more scientifically important than commercially dominant.
